Abstract
Chemo- and radiotherapies that target DNA are the mainstay of cancer treatment. In response to DNA damage, cells are arrested in multiple checkpoints in the cell cycle to allow the damaged DNA to be repaired before progressing into mitosis. Normal cells are arrested in the G1 phase mediated by the p53 tumor suppressor, and p53-deficient cancer cells are arrested in the S or G2 phase. Checkpoint kinase 1 (Chk 1) is a serine / threonine protein kinase and a key mediator in the DNA damage-induced checkpoint network. When the G2 or S checkpoint is abrogated by the inhibition of Chk1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, Chk1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient. This review discusses the rationale of Chk1 as an anticancer target, the structural basis for designing Chk1 inhibitors, and recently disclosed Chk1 inhibitors.
Keywords: Chk1 inhibitor, Anticancer agent, DNA-damaging agent, Adjuvant therapy, DNA damage, Cell cycle, checkpoint, Kinase, Singnal transduction
Anti-Cancer Agents in Medicinal Chemistry
Title: Chk1 Inhibitors for Novel Cancer Treatment
Volume: 6 Issue: 4
Author(s): Zhi-Fu Tao and Nan-Horng Lin
Affiliation:
Keywords: Chk1 inhibitor, Anticancer agent, DNA-damaging agent, Adjuvant therapy, DNA damage, Cell cycle, checkpoint, Kinase, Singnal transduction
Abstract: Chemo- and radiotherapies that target DNA are the mainstay of cancer treatment. In response to DNA damage, cells are arrested in multiple checkpoints in the cell cycle to allow the damaged DNA to be repaired before progressing into mitosis. Normal cells are arrested in the G1 phase mediated by the p53 tumor suppressor, and p53-deficient cancer cells are arrested in the S or G2 phase. Checkpoint kinase 1 (Chk 1) is a serine / threonine protein kinase and a key mediator in the DNA damage-induced checkpoint network. When the G2 or S checkpoint is abrogated by the inhibition of Chk1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, Chk1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient. This review discusses the rationale of Chk1 as an anticancer target, the structural basis for designing Chk1 inhibitors, and recently disclosed Chk1 inhibitors.
Export Options
About this article
Cite this article as:
Tao Zhi-Fu and Lin Nan-Horng, Chk1 Inhibitors for Novel Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/187152006777698132
DOI https://dx.doi.org/10.2174/187152006777698132 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of MicroRNA in the Diagnosis and Therapy of Hepatocellular Carcinoma: A New Frontier
MicroRNA Editorial (Hot Topic: New Drug Design Based on Multi-Targets and System Biology Approach in Light of Real Time DNA Sequencing Technologies)
Current Topics in Medicinal Chemistry Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Antibodies in Diagnostic Applications
Current Pharmaceutical Biotechnology Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Current Drug Targets “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Polyphenols and Aging
Current Aging Science General Aspects of Metal Toxicity
Current Medicinal Chemistry Development of Specific New ELISA for Bioanalysis of Cetuximab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Pharmaceutical Analysis Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer
Current Molecular Medicine Patent Selections
Recent Patents on Food, Nutrition & Agriculture